China Oncology ›› 2023, Vol. 33 ›› Issue (6): 605-612.doi: 10.19401/j.cnki.1007-3639.2023.06.008
• Article • Previous Articles Next Articles
Received:
2023-03-31
Revised:
2023-04-16
Online:
2023-06-30
Published:
2023-07-26
Share article
CLC Number:
ZOU Ting, LIU Xiaowen. Analysis of efficacy of hepatectomy and prognostic risk factors in patients with gastric cancer with synchronous liver metastasis[J]. China Oncology, 2023, 33(6): 605-612.
Tab.1
Clinicopathological data of 79 patients with gastric cancer with synchronous liver metastases"
Factor | n (%) | Factor | n (%) | |
---|---|---|---|---|
Gender | Hepatic tumor distribution | |||
Male | 67 (85) | Unilateral | 50 (63) | |
Female | 12 (15) | Bilateral | 28 (36) | |
Age/year | NA | 1 (1) | ||
≤60 | 31 (39) | Metastatic tumor number | ||
>60 | 48 (61) | Single | 41 (52) | |
Primary tumor size D/cm | Multiple | 37 (47) | ||
≤5 | 37 (47) | NA | 1 (1) | |
>5 | 37 (47) | Hepatectomy | ||
NA | 5 (6) | Yes | 34 (43) | |
Location | No | 45 (57) | ||
Upper-middle | 37 (47) | Peritoneal metastasis | ||
Lower | 39 (49) | Yes | 0 (0) | |
NA | 3 (4) | No | 79 (100) | |
Depth of invasion | Serum AFP level at diagnosis | |||
T1-2 | 7 (9) | Normal | 50 (63) | |
T3-4 | 42 (53) | Elevated | 7 (9) | |
NA | 30 (38) | NA | 22 (28) | |
Lymph node metastasis | Serum CEA level at diagnosis | |||
N0-1 | 14 (18) | Normal | 32 (40) | |
N2-3 | 35 (44) | Elevated | 25 (32) | |
NA | 30 (38) | NA | 22 (28) | |
Differentiated degree | Synchronous liver metastases | |||
Well/moderate | 25 (32) | Yes | 79 (100) | |
Poor | 30 (38) | No | 0 (0) | |
NA | 24 (30) | |||
Metastatic tumor size D/cm | ||||
≤3 | 41 (52) | |||
>3 | 7 (9) | |||
NA | 31 (39) |
Tab. 2
Univariate and multivariate analysis of OS in patients with gastric cancer with synchronous liver metastases"
Data | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
P value | HR | 95% CI | P value | ||
Gender | 0.992 | ||||
Age/year | 0.879 | ||||
Primary tumor size D/cm | 0.046 | 0.662 | 0.164-2.666 | 0.562 | |
Location | 0.136 | ||||
Depth of invasion | 0.087 | ||||
Number of lymph nodes | 0.087 | 2.055 | 0.359-11.746 | 0.418 | |
Differentiated degree | 0.001 | 0.185 | 0.034-1.011 | 0.052 | |
Metastatic tumor size D/cm | 0.360 | 0.593 | 0.092-3.812 | 0.582 | |
Hepatic tumor distribution | 0.038 | 37.253 | 2.577-538.447 | 0.008 | |
Metastatic tumor number | 0.456 | 1.790 | 0.303-10.581 | 0.521 | |
Hepatectomy | 0.000 | 0.149 | 0.023-0.948 | 0.044 | |
Serum AFP level at diagnosis | 0.000 | 8.554 | 0.851-86.032 | 0.068 | |
Serum CEA level at diagnosis | 0.149 |
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.v71.3 |
[2] |
FERLAY J, STELIAROVA-FOUCHER E, LORTET-TIEULENT J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012[J]. Eur J Cancer, 2013, 49(6): 1374-1403.
doi: 10.1016/j.ejca.2012.12.027 pmid: 23485231 |
[3] |
SHAH M A, KELSEN D P. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease[J]. J Natl Compr Canc Netw, 2010, 8(4): 437-447.
doi: 10.6004/jnccn.2010.0033 |
[4] |
CONDE MONROY D, IBAÑEZ-PINILLA M, SABOGAL J C, et al. Survival outcomes of hepatectomy in gastric cancer liver metastasis: a systematic review and meta-analysis[J]. J Clin Med, 2023, 12(2): 704.
doi: 10.3390/jcm12020704 |
[5] |
GARANCINI M, UGGERI F, DEGRATE L, et al. Surgical treatment of liver metastases of gastric cancer: is local treatment in a systemic disease worthwhile?[J]. HPB (Oxford), 2012, 14(3): 209-215.
doi: 10.1111/j.1477-2574.2011.00428.x |
[6] |
MIKI Y, FUJITANI K, HIRAO M, et al. Significance of surgical treatment of liver metastases from gastric cancer[J]. Anticancer Res, 2012, 32(2): 665-670.
pmid: 22287760 |
[7] |
ROMANO F, GARANCINI M, UGGERI F, et al. Surgical treatment of liver metastases of gastric cancer: state of the art[J]. World J Surg Oncol, 2012, 10: 157.
doi: 10.1186/1477-7819-10-157 pmid: 22862882 |
[8] |
CHEN L, SONG M Q, LIN H Z, et al. Chemotherapy and resection for gastric cancer with synchronous liver metastases[J]. World J Gastroenterol, 2013, 19(13): 2097-2103.
doi: 10.3748/wjg.v19.i13.2097 |
[9] |
FUJITANI K, YANG H K, MIZUSAWA J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial[J]. Lancet Oncol, 2016, 17(3): 309-318.
doi: S1470-2045(15)00553-7 pmid: 26822397 |
[10] |
GRANIERI S, ALTOMARE M, BRUNO F, et al. Surgical treatment of gastric cancer liver metastases: systematic review and meta-analysis of long-term outcomes and prognostic factors[J]. Crit Rev Oncol Hematol, 2021, 163: 103313.
doi: 10.1016/j.critrevonc.2021.103313 |
[11] | MINCIUNA C E, TUDOR S, MICU A, et al. Safety and efficacy of simultaneous resection of gastric carcinoma and synchronous liver metastasis-a western center experience[J]. Medicina (Kaunas), 2022, 58(12): 1802. |
[12] |
YAMAGUCHI T, TAKASHIMA A, NAGASHIMA K, et al. Evaluating the efficacy of post-operative chemotherapy after curative resection of stage Ⅳ gastric cancer with synchronous oligo metastasis: a multicenter retrospective study[J]. Gastric Cancer, 2023, 26(2): 307-316.
doi: 10.1007/s10120-023-01363-8 |
[13] |
CUI J K, LIU M, SHANG X K. Hepatectomy for liver metastasis of gastric cancer: a meta-analysis[J]. Surg Innov, 2019, 26(6): 692-697.
doi: 10.1177/1553350619856491 |
[14] |
OCHIAI T, SASAKO M, MIZUNO S, et al. Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors[J]. Br J Surg, 1994, 81(8): 1175-1178.
doi: 10.1002/bjs.1800810832 |
[15] |
MARTE G, TUFO A, STECCANELLA F, et al. Efficacy of surgery for the treatment of gastric cancer liver metastases: a systematic review of the literature and meta-analysis of prognostic factors[J]. J Clin Med, 2021, 10(5): 1141.
doi: 10.3390/jcm10051141 |
[16] |
OHKURA Y, SHINOHARA H, HARUTA S, et al. Hepatectomy offers superior survival compared with non-surgical treatment for≤3 metastatic tumors with diameters < 3 cm from gastric cancer: a retrospective study[J]. World J Surg, 2015, 39(11): 2757-2763.
doi: 10.1007/s00268-015-3151-0 |
[17] |
OKI E, TOKUNAGA S, EMI Y, et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302)[J]. Gastric Cancer, 2016, 19(3): 968-976.
doi: 10.1007/s10120-015-0530-z pmid: 26260876 |
[18] |
WANG Y N, SHEN K T, LING J Q, et al. Prognostic analysis of combined curative resection of the stomach and liver lesions in 30 gastric cancer patients with synchronous liver metastases[J]. BMC Surg, 2012, 12: 20.
doi: 10.1186/1471-2482-12-20 |
[19] |
KINOSHITA T, KINOSHITA T, SAIURA A, et al. Multicentre analysis of long-term outcome after surgical resection for gastric cancer liver metastases[J]. Br J Surg, 2015, 102(1): 102-107.
doi: 10.1002/bjs.9684 pmid: 25389030 |
[20] |
TIBERIO G A, MINISTRINI S, GARDINI A, et al. Factors influencing survival after hepatectomy for metastases from gastric cancer[J]. Eur J Surg Oncol, 2016, 42(8): 1229-1235.
doi: 10.1016/j.ejso.2016.03.030 pmid: 27134189 |
[21] |
UGGERI F, RIPAMONTI L, PINOTTI E, et al. Is there a role for treatment-oriented surgery in liver metastases from gastric cancer?[J]. World J Clin Oncol, 2020, 11(7): 477-494.
doi: 10.5306/wjco.v11.i7.477 pmid: 32821653 |
[22] |
CHEN J, TANG Z, DONG X, et al. Radiofrequency ablation for liver metastasis from gastric cancer[J]. Eur J Surg Oncol, 2013, 39(7): 701-706.
doi: 10.1016/j.ejso.2013.03.023 pmid: 23597495 |
[23] | ZHANG K C, CHEN L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases[J]. Ther Adv Med Oncol, 2020, 12: 1758835920904803. |
[24] |
KATAOKA K, KINOSHITA T, MOEHLER M, et al. Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG[J]. Gastric Cancer, 2017, 20(5): 904-912.
doi: 10.1007/s10120-017-0696-7 pmid: 28150070 |
[25] |
VIGANÒ L, VELLONE M, FERRERO A, et al. Liver resection for gastric cancer metastases[J]. Hepato-gastroenterology, 2013, 60(123): 557-562.
pmid: 23635434 |
[26] |
YUKAMI H, KAWAZOE A, LIN Y T, et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials[J]. Clin Cancer Res, 2022, 28(16): 3480-3488.
doi: 10.1158/1078-0432.CCR-22-0630 pmid: 35679062 |
[1] | LIU Shuai, ZHANG Kai, ZHANG Xiaoqing, LUAN Wei. An exploratory study on the perioperative treatment of locally advanced gastric cancer with combination of penpulimab, anlotinib and chemotherapy [J]. China Oncology, 2024, 34(7): 659-668. |
[2] | WANG Fei, LIU Pei, HU Nan. Effect of bevacizumab assisted PD-1 inhibitor on serum miR-20a-5p and miR-515-3p in the treatment of gastric cancer [J]. China Oncology, 2024, 34(5): 493-500. |
[3] | Professional Committee on Gastric Cancer of Shanghai Anticancer Association , Professional Committee on Gastrointestinal Cancer of China Association for Promotion of Health Science and Technology . Chinese expert consensus on clinical practice of locally advanced gastric cancer invading adjacent organs (2024 edition) [J]. China Oncology, 2024, 34(5): 517-526. |
[4] | XU Yonghu, XU Dazhi. Progress and prospects of gastric cancer treatment in the 21st century [J]. China Oncology, 2024, 34(3): 239-249. |
[5] | WANG Xuefei, ZHOU Peng, TANG Zhaoqing. New progress and development trend of surgical treatment for gastric cancer [J]. China Oncology, 2024, 34(3): 250-258. |
[6] | XUE Chi, GAO Peng, ZHU Zhi, WANG Zhenning. Application and challenge of immunotherapy in perioperative therapy of gastric cancer [J]. China Oncology, 2024, 34(3): 259-267. |
[7] | SHEN Jie, WANG Jiangli, WANG Zezhou, MO Miao, ZHOU Changming, YUAN Jing, XU Dazhi, ZHENG Ying. Survival analysis of 6 737 surgically resected gastric cancer cases in China from a large single institution hospital-based cancer registry database [J]. China Oncology, 2024, 34(3): 268-277. |
[8] | LI Jing, ZHENG Lei, GAO Yu. Analysis of effects of trastuzumab assisted modified DOF fortnightly regimen on serum tumor markers and survival rate in patients with cisplatin-resistant gastric cancer [J]. China Oncology, 2024, 34(3): 286-292. |
[9] | FENG Huizhi, LIU Jingmei, BU Xiaoqian. A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer [J]. China Oncology, 2024, 34(11): 1028-1035. |
[10] | SUN Yang, WANG Lian, ZHAO Meng, ZHANG Xiaofeng, GENG Zhijun, WANG Yueyue, SONG Xue, ZUO Lugen, LI Jing, HU Jianguo. The prognostic value of high expression of FKBP1A in gastric cancer and the regulatory effect of targeted PI3K/AKT on glucose metabolism [J]. China Oncology, 2023, 33(8): 726-739. |
[11] | SUN Chongyuan, ZHAO Dongbing. The progress and future prospects of the application of circulating tumor DNA in the diagnosis and treatment of gastric cancer [J]. China Oncology, 2023, 33(8): 782-789. |
[12] | KANG Yinnan, CHEN Shun, XIE Youcheng, ZHENG Ying, HE Yujing, LI Chuyi, YU Xiaohui. Application and research progress of antibody drug conjugates in HER2 positive advanced gastric cancer [J]. China Oncology, 2023, 33(8): 790-800. |
[13] | DU Shuxiang, ZHAO Yingzhi, ZHANG Xuetao, WANG Tao, LUO Jingyu, ZHANG Wei, WU Gang. Analysis of group 12a lymph node metastasis at different sites of gastric adenocarcinoma and its risk factors [J]. China Oncology, 2023, 33(6): 597-604. |
[14] | JIANG Jinling, ZHOU Chenfei, WANG Chao, ZHAO Liqin, WU Junwei, ZHANG Jun. Advanced progress in research and diagnosis of gastric cancer in 2022 [J]. China Oncology, 2023, 33(4): 303-314. |
[15] | XIAO Lanshu, PAN Liudi, LIU Yi, WANG Jie, CHEN Hui. LncRNA DLEU7-AS1 contributes to proliferation and migration of gastric cancer by regulating MSN transcription [J]. China Oncology, 2023, 33(4): 327-341. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd